Pimecrolimus and tacrolimus: the US FDA public health advisory.
Division of Dermatology, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
S
S
Maddin
D000287:Administration, Topical; D065095:Calcineurin Inhibitors; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016559:Tacrolimus / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; C117268:pimecrolimus; D016559:Tacrolimus